Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2025 07:45 ET | Source: Research and Markets

CAR T-Cell Therapy Market Forecasts to 2035, with Competitor Profiles of Autolus, Bluebird Bio, Carsgen Therapeutics, Cellectis, Noile-Immune Biotech, Shanghai GeneChem, Takara Bio and More

Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy Market Industry Trends and Global Forecasts to 2035" report has been added to ResearchAndMarkets.com's offering. The global CAR...
January 16, 2025 04:43 ET | Source: Research and Markets

Cell Therapy Technologies Market Forecasts 2024-2029: Advancements in Gene Editing Technologies, Development of Automated Cell Processing Systems and Regulatory Support for Fast-tracking Therapies

Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Vessels, Single-Use Equipment), Process (Cell Processing, Preservation,...
January 03, 2025 04:09 ET | Source: Research and Markets

CAR-T Cell Therapy Market Research 2024-2025: Navigating the CAR-T Landscape, Major Players, Recent Approvals, and Pioneering Therapies

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025" report has been added to ResearchAndMarkets.com's offering. This...
December 19, 2024 08:30 ET | Source: Tevogen Bio Inc

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
December 12, 2024 05:38 ET | Source: Research and Markets

Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028

Dublin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- The "Allogeneic T Cell Therapies Market, 2024-2028 & 2033" report has been added to ResearchAndMarkets.com's offering. The allogeneic T cell...
December 02, 2024 06:31 ET | Source: Research and Markets

CAR T-cell Therapy Strategic Business Research Report 2024: Global Market to Reach $10.8 Billion by 2030 - Expanding Clinical Applications Beyond Blood Cancers Expands Opportunities

Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "CAR T-cell Therapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CAR T-cell...
November 29, 2024 04:43 ET | Source: Research and Markets

Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More

Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (GRNA Synthesis & Vector Construction), Technique, Technology...
November 29, 2024 04:24 ET | Source: Research and Markets

Cell and Gene Therapy Tools and Reagents Market Report 2024 - Driving Medical Advances: Cell and Gene Therapy Tools Market to Hit $16.7 Billion by 2029

Dublin, Nov. 29, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents Market" report has been added to ResearchAndMarkets.com's offering.The Cell and Gene Therapy Tools and...
November 15, 2024 11:02 ET | Source: Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 15, 2024 11:01 ET | Source: Barinthus Biotherapeutics

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right